Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1. fázis

Study Evaluating Safety & Tolerability of Migaldendranib in US Healthy Volunteers

A legfontosabb adatok

Ki végzi
Ashvattha Therapeutics, Inc.
Hol
Cincinnati (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
1. fázis
Résztvevők
24 fő, tervezett
Kezdés
2026. aug. 12.
Várható befejezés
2026. nov. 20.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • Weekly subcutaneous administration of Migaldendranib (MGB)
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Healthy man or woman age 18 to 65 years, inclusive, at the Screening Visit
  • Has the ability to understand and sign the written ICF and local medical privacy authorization forms, which must be obtained prior to any study-related procedures being completed
  • Is in general good health, based upon the results of a medical history assessment, physical examination, vital signs, and laboratory profile, as judged by the Investigator
  • Female participants of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 1 year, with follicle-stimulating hormone (FSH) in the postmenopausal range at Screening, based on the central laboratory's ranges
  • All female participants of childbearing potential with male partners and male participants with female partners of childbearing potential must consent to use 2 highly effective methods of contraception from start of study and for at least 90 days following the end of study (EOS) visit or last dose of study treatment, whichever is later. Women of childbearing potential on hormonal contraceptives must be stable on the medication for at least 2 menstrual cycles prior to Day -1
  • The following are acceptable methods of highly effective contraception:; Using twice the normal protection of birth control by using a condom AND one other form of contraception; either birth control pills ("The Pill") or injectable birth control, birth control patch or contraceptive implant associated with inhibition of ovulation, or intrauterine device; or; Surgical sterilization as a single form of birth control: i.e., tubal ligation, hysterectomy, bilateral oophorectomy, vasectomy, or equivalently effective surgical form of birth control (with documented proof of the absence of sperm in the post-vasectomy ejaculate) at least 6 months prior to Screening; or; True sexual abstinence for the duration of the study and for at least 90 days following the EOS visit or after the last dose of IP, whichever is later, is acceptable only when in line with the preferred and usual lifestyle of the participant; Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not considered "true" abstinence and are not acceptable methods of contraception
  • If male, participants must agree to abstain from sperm donation through 90 days after administration of the last dose of study drug
  • If female, participants must refrain from donation of ova from start of study and for 90 days after last dose of investigational drug
  • Female participants must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Check-in (Day -1) and must not be pregnant, lactating, or planning to become pregnant during their participation in the study and for at least 90 days after the last dose of study drug
  • Participants must have a negative test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVab), and human immunodeficiency virus (HIV) antibody at Screening
  • Participants must have an estimated glomerular filtration rate (eGFR) of greater than or equal to 60 mL/min/1.73 m2 at Screening
  • Participants must have a negative urine test for drugs of abuse, cotinine, and breath alcohol test at Screening and Check-in (Day -1)
  • Participants must be willing and able to abide by all study requirements and restrictions throughout the duration of the study

Ki nem vehet részt

  • Has had an acute illness considered clinically significant by the Investigator within 30 days prior to Screening
  • History of alcoholism or drug abuse within 1 year prior to Screening or excessive alcohol consumption defined as >14 units per week. One unit of alcohol equals 12 oz (360 mL) beer, 1.5 oz (45 mL) liquor, or 5 oz (150 mL) wine 14 standard drinks per week
  • Has used any product containing nicotine within 30 days prior to Screening or intends to use any product containing nicotine during the study
  • Has had any immunizations (live vaccines) in the 4 weeks prior to Screening; COVID-19 vaccination within 7 days of Day 1
  • Has used any prescription (with the exception of hormonal contraceptives) or over the counter medication (with the exception of acetaminophen), vitamins/herbal supplements within7 days prior to Day 1
  • Has used any other study drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to Day 1
  • Has lost or donated greater than or equal to 500 mL of whole blood or blood products within 8 weeks prior to Screening
  • Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, immunologic, allergic disease (including multiple or clinically significant drug allergies), or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the participant at an unacceptable risk as a participant in this study
  • History of malignancy (other than successfully treated basal cell or squamous cell skin cancer)
  • Positive for severe acute respiratory syndrome coronavirus 2 on Day -1
  • Evidence of systemic inflammation as measured by C-reactive protein (CRP) above the upper limit of normal, as measured by the central laboratory
  • Laboratory results (serum chemistry, hematology, coagulation, and urinalysis) outside the normal range at Screening and/or Check-in (Day -1) and considered clinically significant in the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and alanine transaminase (ALT) above the upper limit of normal at Screening and/or Check-in (Day -1) is exclusionary. One retest of an exclusionary laboratory result is allowed at the discretion of the Investigator
  • History or presence of an abnormal electrocardiogram (ECG) that, in the opinion of the Investigator, is clinically significant
  • Investigator has reason to believe that the participant may be unable to fulfill the protocol visit schedule or requirements
  • Has any finding that, in the view of the Investigator or Medical Monitor, would compromise the participant's safety requirements
  • Is employed by the Sponsor, the Contract Research Organization (CRO), or the study site (permanent, temporary contract worker, or designee responsible for the conduct of the study), or is a family member (spouse, parent, sibling, or child) of the Sponsor, CRO, or study site employee

Helyszínek itt: Egyesült Államok

  • Medpace Clinical Pharmacology UnitCincinnati, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 24 healthy volunteers at 1 site in the United States.

A vizsgálat 4 csoportja

  • MGB 200 mg Formulation 1A vizsgált kezelés

    Participants receive MGB 200 mg Formulation 1 administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.

    Kezelés: Weekly subcutaneous administration of Migaldendranib (MGB)

  • MGB 200 mg Formulation 2A vizsgált kezelés

    Participants receive MGB 200 mg Formulation 2 administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.

    Kezelés: Weekly subcutaneous administration of Migaldendranib (MGB)

  • MGB 400 mgA vizsgált kezelés

    Participants receive MGB 400 mg administered subcutaneously once weekly on Days 1, 8, and 15 following Safety Review Committee approval.

    Kezelés: Weekly subcutaneous administration of Migaldendranib (MGB)

  • Experimental: To Be Determined (Optional Arm)A vizsgált kezelés

    This optional arm will be used if recommended by the Safety Review Committee. Dosage TBD.

    Kezelés: Weekly subcutaneous administration of Migaldendranib (MGB)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Migaldendranib (MGB) in Healthy Volunteers
A regiszteradat frissítve
2026. november 17.